Patients are usually categorized into low-, intermediate- and high-risk (LR, IR, HR) groups based on clinical stage, age at diagnosis, tumor histology, MYCN oncogene amplification and chromosomal ploidy. This evidence concerns the gene MYCN and neoplasm.